Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998)
about
Large granular lymphocytic leukemia. Current diagnostic and therapeutic approaches and novel treatment options.Vitamin D decreases STAT phosphorylation and inflammatory cytokine output in T-LGL leukemia.Activating somatic mutations outside the SH2-domain of STAT3 in LGL leukemia.Sphingosine kinase inhibitors decrease viability and induce cell death in natural killer-large granular lymphocyte leukemia.Alemtuzumab in T-cell large granular lymphocytic leukaemia: interim results from a single-arm, open-label, phase 2 studyAtypical aleukemic presentation of large granular lymphocytic leukemia: a case report.Methotrexate therapy of T-cell large granular lymphocytic leukemia impact of STAT3 mutation.Calcitriol-mediated reduction in IFN-γ output in T cell large granular lymphocytic leukemia requires vitamin D receptor upregulation.How we diagnose and treat neutropenia in adults.Lymphoma classification update: T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms.Moderate-dose cyclophosphamide in the treatment of relapsed/refractory T-cell large granular lymphocytic leukemia-associated pure red cell aplasia.Clinical Features, Pathogenesis, and Treatment of Large Granular Lymphocyte Leukemias.STAT3 mutation impacts biological and clinical features of T-LGL leukemia.Prolonged complete hematologic response in relapsed/refractory T-large granular lymphocyte leukemia after bendamustine treatment.Concepts in mature T-cell lymphomas - highlights from an international joint symposium on T-cell immunology and oncology.TRAIL mediates and sustains constitutive NF-κB activation in LGL leukemia.Dysregulation of the IFN-γ-STAT1 signaling pathway in a cell line model of large granular lymphocyte leukemia.Indolent, T-cell, large granular lymphocytic leukaemia in a dog presenting with severe neutropenia and an absence of lymphocytosis.
P2860
Q30238757-899CB4CF-F87F-49F1-9157-2C214A774A56Q30275771-8DE229A2-33E1-4B75-89C1-E1AF3822C8ACQ30278603-AC0D5E20-6332-4883-A704-D7BDFA76A8B4Q30278883-189B3F48-1C21-49BE-89FC-957040DAAD0FQ36486302-7060D96E-F8E5-4C75-A7C5-8955DF3CF556Q37530828-0A545A14-6CFE-4400-B1A0-B4B8B5774762Q37641621-55B5E5B8-1424-4921-B17D-0BA1FF4E5C56Q38696547-5C5BE67F-21D3-449A-B0AF-5014748ABE6BQ38700289-9D4831EB-E78F-4BDF-8508-AE1B530C2724Q38992646-6D029A8E-6DBD-4371-AF8F-7604C275D996Q39851542-C85A5E47-A35B-4BB9-B6A7-711580A169EBQ41307812-0EB14CA5-2719-4872-91F1-9FA8823E7C6EQ42038683-ABF3EECE-FC93-4DB8-B7B0-A0181C518C0FQ42364241-2A755BB7-3F87-417E-B218-0A82CA57BC11Q48793063-A2AE64A5-DC5B-46DB-8CE4-F72A047785B0Q52716419-49AFA8C1-6373-475E-8AF7-A59D0AC1A5FCQ52730781-1BEED7DA-7B47-4CC5-A478-997C6D984AD5Q55242300-8296068C-B5DA-44FF-A2B4-3A2C0EE31059
P2860
Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998)
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Immunosuppressive therapy of L ...... erative Oncology Group (E5998)
@ast
Immunosuppressive therapy of L ...... erative Oncology Group (E5998)
@en
type
label
Immunosuppressive therapy of L ...... erative Oncology Group (E5998)
@ast
Immunosuppressive therapy of L ...... erative Oncology Group (E5998)
@en
prefLabel
Immunosuppressive therapy of L ...... erative Oncology Group (E5998)
@ast
Immunosuppressive therapy of L ...... erative Oncology Group (E5998)
@en
P2093
P2860
P50
P356
P1433
P1476
Immunosuppressive therapy of L ...... erative Oncology Group (E5998)
@en
P2093
H L M Rajala
H M Lazarus
J M Bennett
M R Litzow
M S Tallman
T P Loughran
P2860
P2888
P304
P356
10.1038/LEU.2014.298
P577
2014-09-13T00:00:00Z
P6179
1002021111